Keliximab is a monoclonal antibody that targets the CD4 receptor on T cells, primarily used in the treatment of autoimmune diseases, particularly rheumatoid arthritis. As a humanized IgG1 antibody, it is designed to modulate the immune response by inhibiting T cell activation and proliferation. This mechanism helps to reduce inflammation and tissue damage associated with autoimmune conditions. Keliximab has a relatively high specificity for its target, which minimizes off-target effects and enhances its therapeutic potential. The substance is administered via injection, and its pharmacokinetics can be influenced by factors such as dosage and patient-specific variables. Clinical studies have demonstrated its efficacy in reducing disease activity and improving quality of life for patients with chronic inflammatory conditions. However, like all biologics, it may be associated with potential side effects, including increased susceptibility to infections and infusion-related reactions. Overall, Keliximab represents a targeted approach in the management of autoimmune disorders, reflecting the advancements in biopharmaceutical development.

Keliximab

174722-30-6: Keliximab is a monoclonal antibody that targets the CD4 receptor on T cells, primarily used in the treatment of autoimmune diseases, particularly rheumatoid arthritis. As a humanized IgG1 antibody, it is designed to modulate the immune response by inhibiting T cell activation and proliferation. This mechanism helps to reduce inflammation and tissue damage associated with autoimmune conditions. Keliximab has a relatively high specificity for its target, which minimizes off-target effects and enhances its therapeutic potential. The substance is administered via injection, and its pharmacokinetics can be influenced by factors such as dosage and patient-specific variables. Clinical studies have demonstrated its efficacy in reducing disease activity and improving quality of life for patients with chronic inflammatory conditions. However, like all biologics, it may be associated with potential side effects, including increased susceptibility to infections and infusion-related reactions. Overall, Keliximab represents a targeted approach in the management of autoimmune disorders, reflecting the advancements in biopharmaceutical development.

<p>Keliximab (SB-210396), a chimeric IgG1 anti-CD4 antibody, inhibits T cells and IL-2, for cancer research, K i 1.0 nM.</p>

<p>A chimeric human/macaque IgG1 anti-CD4 monoclonal antibody</p>

CAS 174722-30-6

Keliximab

Keliximab

Ref: TM-T77049

Keliximab

Ref: 3D-CLA1127